Dengue Academy is intended for an international audience of healthcare professionals outside of the US and UK.
This website has been initiated and developed by Takeda

© Copyright 2022 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.
VV-MEDMAT-55340, Date of preparation: November 2021

Dealing with Dengue

Resources for patient support

Takeda

3 minutes
Impact of the COVID-19 Pandemic on the Global Dengue Situation

ADVA

79 minutes
Randomised trials of Wolbachia for dengue control – a step towards elimination?

ADVA

50 minutes
Managing the severely ill dengue patients – Adult and Paediatric Intensivists

ADVA

92 minutes
Management of cases

Takeda

1 minutes
Covid-19 and dengue: Double punches for dengue-endemic countries in Asia

Takeda

2 minutes
Case report: Acute vision loss in a young returning traveler with dengue fever

Takeda

2 minutes
Experience of a tertiary hospital in Singapore managing a dual outbreak of COVID and dengue

Takeda

2 minutes
Dengue and post-infection fatigue: findings from a prospective cohort study

Takeda

2 minutes
Zika and dengue but not chikungunya are associated with Guillain–Barré syndrome in Mexico: A case-control study

Takeda

2 minutes

Dengue Academy is intended for an international audience of healthcare professionals outside of the US and UK.
This website has been initiated and developed by Takeda